Clearside Biomedical (NASDAQ:CLSD - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03, Zacks reports. The business had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.27 million.
Clearside Biomedical Trading Down 3.4 %
Shares of CLSD traded down $0.03 on Monday, reaching $0.92. 89,092 shares of the company's stock traded hands, compared to its average volume of 354,694. The stock's 50 day simple moving average is $0.96 and its two-hundred day simple moving average is $1.04. Clearside Biomedical has a 52-week low of $0.77 and a 52-week high of $1.65. The stock has a market cap of $69.62 million, a PE ratio of -2.04 and a beta of 2.10.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on CLSD shares. Chardan Capital restated a "buy" rating and issued a $6.00 target price on shares of Clearside Biomedical in a report on Friday. Needham & Company LLC lowered their price objective on Clearside Biomedical from $6.00 to $4.00 and set a "buy" rating for the company in a research note on Friday. StockNews.com cut Clearside Biomedical from a "hold" rating to a "sell" rating in a research report on Tuesday, March 18th. Finally, HC Wainwright reissued a "buy" rating and issued a $6.00 price target on shares of Clearside Biomedical in a research report on Monday. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $5.25.
Check Out Our Latest Research Report on CLSD
Clearside Biomedical Company Profile
(
Get Free Report)
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Featured Stories
Before you consider Clearside Biomedical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clearside Biomedical wasn't on the list.
While Clearside Biomedical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
